Background
Juvenile idiopathic arthritis (JIA) is the most common chronic disease in childhood with a global prevalence varying between 3.8 – 400 per 100,000 [
1]. It is not a single disease, but comprises all forms of idiopathic arthritis lasting for more than 6 weeks before the age of 16 [
2,
3]. The International League of Associations for Rheumatology (ILAR) has classified seven categories of JIA with distinct clinical and laboratory features [
4]. JIA may cause severe disability and a reduced quality of life. Drugs used in the management of JIA are nonsteroidal anti-inflammatory drugs (NSAIDs), intraarticular and systemic glucocorticoids, and conventional synthetic (cs-) and biological (b-) disease-modifying antirheumatic drugs (DMARDs) [
5‐
7]. Due to therapeutic advances in the last two decades, such as the availability of b-DMARDs, disease remission has become a realistic goal for most children with JIA [
8].
Two of the most used b-DMARDs in the management of non-systemic arthritis in JIA are the TNF-α inhibitors etanercept (ETN) and adalimumab (ADA). Current treatment recommendations for JIA consider ETN and ADA equal alternatives [
5]. Unlike ADA, ETN is not effective against uveitis, an ocular manifestation that affects roughly 1 in every 5 JIA patients [
9]. A 2013 study found that ETN is prescribed more often than ADA in daily practice, although JIA patients with a history or at high risk of developing uveitis are more commonly treated with ADA [
10]. According to this study, the choice for ETN or ADA treatment primarily depends on physician and patient preferences such as experience with the drug.
While ETN and ADA are considered equally effective in treating arthritis in JIA, no studies have compared their impact on patient-reported evaluation of overall well-being. Patient-reported outcomes such as well-being are important measures in a treat-to-target approach to the management of JIA since they provide a more holistic view of health condition and treatment efficacy than merely disease activity [
11‐
14]. Data on patient well-being after drug therapies might therefore be valuable for making treatment guidelines and recommendations.
The objective of this research was to determine whether ETN and ADA have a differential effect on well-being in patients with non-systemic JIA from the international observational Pharmachild registry [
15‐
18]. We hypothesized that such a difference might be caused by differences in type of side effects, methotrexate (MTX) co-medication (which is more common with ADA in order to prevent anti-drug antibody development) and frequency of the injection ( which is higher for ETN).
Discussion
In our study, ETN and ADA both improved VAS well-being following 3–12 months of treatment. Analysis of 90 matched patients indicates improvement of well-being may be larger when ETN therapy is prescribed compared to ADA, but results were non-significant. The same conclusions were drawn following a sensitivity analysis in which we used the transformed propensity score for statistical adjustment instead of matching.
Propensity score matching at baseline resulted in overall equally distributed covariates for ETN and ADA starters. However, a difference in median disease duration of over 1 year was observed. It could be that ADA was used earlier in the disease course due to risk of uveitis, which is highest during the first years after onset of arthritis [
34]. Nevertheless, when adjusting for baseline disease duration in our analyses, similar results were observed.
We report the first head-to-head comparison of the effects of ETN and ADA on patient-reported evaluation of overall well-being in JIA. Previous studies have reported patient-reported well-being after initiation of ETN or ADA therapy, but did not compare the two drugs [
35‐
37]. In these studies, well-being after anti-TNF therapy improved more compared to the current study, although patients were older, had higher disease activity and could have had systemic arthritis or a history of uveitis. In the current study, VAS well-being scores at follow-up were significantly better for ETN starters compared to ADA starters and the estimated improvement in VAS well-being from baseline was 0.89 points larger for ETN starters compared to ADA starters. The latter difference was however not statistically significant. This may reflect equality between the treatments or a lack of statistical power of our study, given the estimated effect with a significance level of 0.05 was extremely close to statistical significance with a
P-value of 0.06. A true difference in effect on VAS well-being might be explained by pain caused by ADA injection [
10]. Pain on ADA injection used to be associated with a citrate buffer, which was removed from the drug in 2018 [
38]. In our study, 89% (40/45) of patients who started ADA did so before 2018. Therefore, it could be that the possible difference in effect on VAS well-being between ETN and ADA is currently smaller than observed in this study.
Similar to the results of our research, previous studies have concluded that ETN and ADA have comparable efficacy in reducing disease activity in JIA [
37,
39‐
42]. However, the evidence from these studies is limited given differences in patient characteristics between the groups of included ETN and ADA users. These differences were mostly observed in uveitis history or earlier b-DMARD use. One study suggested that children younger than 4 years without uveitis show a better response to ETN than ADA [
43]. But more research on this subject is required given the risk of de novo uveitis and the fact that ETN and ADA users within this study were also not comparable.
Since the current study did not demonstrate a statistically significant difference in effect on well-being, disease activity and adverse events, presence or risk of uveitis remains the most important factor for physicians to consider when choosing between ETN and ADA. ADA but not ETN is effective against uveitis [
9], although development of uveitis has also been reported under ADA therapy [
44]. JIA-associated uveitis is extremely rare in patients with systemic arthritis or RF + polyarthritis and occurs most often in ANA positive patients with a young age at JIA onset [
17]. Too few uveitis events were observed in the current study to make any comparisons, although the only case of uveitis occurred in the ETN group. Another important factor in choosing between ETN or ADA therapy is possible treatment failure due to development of anti-drug antibodies, which can occur under ADA therapy and can be prevented with MTX co-medication [
45]. Adverse events related to MTX are however common and include nausea, gastro-intestinal complaints, mouth ulcers and hepatotoxicity [
7]. For these reasons, physicians might opt for ETN instead of ADA therapy, especially in patients with MTX intolerance.
An interesting finding of our study was that well-being considerably worsened during follow-up in 6 patients, although disease activity improved in nearly all patients included in the study. This could possibly be explained by fear of injection, but we could not confirm this hypothesis from JAMARs at follow-up of the concerned patients. Another reason might be chronic pain due to central sensitization, which is not uncommon in JIA [
46]. We indeed observed that 4 out of the 6 patients reported a suboptimal VAS pain score and persistent activity or relapse, despite that disease activity, as indicated by physician-reported active and painful joint counts, was absent or minimal. Also, none of these patients developed uveitis. These results show that physician-reported disease activity does not translate directly to well-being in children with JIA.
Our study has limitations. Almost all patients were eventually included from European centers, which might hamper generalization of our results to other settings around the world where b-DMARDs are not widely available [
47]. Patients from non-European centers were mostly excluded for not having completed a JAMAR on the day of starting ETN or ADA therapy or at maximum 1 month earlier. Furthermore, the number of patients included in our study was not large enough to draw conclusions about differences in the type of adverse events reported between ETN and ADA starters. Especially considering that a proportion of the reported adverse events were likely caused by MTX co-medication [
48], which was common and similar for both ETN and ADA starters at baseline and follow-up. Also, given the observational nature of this study, JAMARs of included patients were not completed at the exact same time points from starting a b-DMARD, further factors associated with uveitis risk such as ANA status and erythrocyte sedimentation rate [
49] could not be used in the propensity score model as predictors of ETN or ADA therapy due to missing data, and there is a possibility of unmeasured confounding variables such as the treating physician. The latter could be a confounder given that some physicians might have a preference for ETN or ADA based on previous experiences.
Nonetheless, propensity score matching is a strong method for dealing with bias in (retrospective) observational studies [
50]. This method mimics the randomization process of a RCT in the context of a non-interventional study [
51]. Indeed, we observed good balance of the many covariates measured in our propensity score-matched cohort. Furthermore, whereas RCTs may prove efficacy of interventions, their results often suffer from limited applicability to clinical practice due to strict inclusion and exclusion criteria. On the other hand, propensity score methods allow for valid comparison of effectiveness of different interventions from “real-world evidence”, which closely resembles the actual clinical practice [
52].
To our knowledge, we report the first comparison between similar groups of b-DMARD therapy-naive ETN and ADA starters in JIA, with a focus on patient-reported well-being. Given the scarcity of such data but its value for treatment guidelines and recommendations, more studies on the effects of drugs from the same classes on patient-reported outcomes in JIA should be performed in the future.
Acknowledgements
The authors thank all PRINTO centers for contributing to the data collection and PRINTO research assistants (Chiara Pallotti, Silvia Scala, Simona Angioloni and Luca Villa). The authors would also like to express their acknowledgements to the European Reference Network for Immunodeficiency, Autoinflammatory, Autoimmune and Pediatric Rheumatic diseases (ERN-RITA). Lastly, we thank all patients and their parents for consenting to this research.
Permission for use of JAMAR and its translations must be obtained in writing from PRINTO, Genoa, Italy. All JAMAR-related inquiries should be directed to at printo@gaslini.org. Permission for use of CHAQ and CHQ derived-material is granted through the scientific cooperation of the copyright holder ICORE of Woodside CA and HealthActCHQ Inc. of Boston, Massachusetts USA. All CHQ-related inquiries should be directed to licensing@healthactchq.com. All CHAQ-related inquiries should be directed to gsingh@stanford.edu.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.